Molecular medicine

Feinstein Institutes report on early mapping of vagus nerve, unveil novel stimulator for bioelectronic medicine research

Retrieved on: 
금요일, 2월 24, 2023
Medical Devices, Hospitals, Clinical Trials, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Biomedical engineering, Vagus nerve stimulation, Diabetes, Feinstein Institutes for Medical Research, Neck, Doctor of Philosophy, Cancer, Paper, Larynx, Anatomy, Inflammatory Bowel Diseases, Credit, Disease, Heart, Interface (computing), Heart rate, Brain, Sensation, Research, Medical research, Neuroscience, Condition, Pulmonary hypertension, Inflammation, Vagus nerve, NIH, VNS, Molecular medicine, Feinstein, Paralysis, Nerve, Map, Arthritis, Sore throat, Multimedia, Bangladesh Technical Education Board, Atrial fibrillation, Nervous system, Medicine, Lung, Medical imaging, Management, Medical device, Pharmaceutical industry, MD

Bioelectronic medicine scientists published their early mapping in the journal Brain Stimulation , along with a novel vagus nerve stimulator that can activate targeted fibers, opening up new avenues of vagus nerve stimulation (VNS) research.

Key Points: 
  • Bioelectronic medicine scientists published their early mapping in the journal Brain Stimulation , along with a novel vagus nerve stimulator that can activate targeted fibers, opening up new avenues of vagus nerve stimulation (VNS) research.
  • View the full release here: https://www.businesswire.com/news/home/20230224005280/en/
    Stavros Zanos, MD, PhD, is senior author on the research, which published in the journal Brain Stimulation.
  • The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine, which combines molecular medicine, neuroscience and biomedical engineering.
  • By producing bioelectronic medicine knowledge, disease and injury could one day be treated with our own nerves without costly and potentially harmful pharmaceuticals.

Review Highlights Growing Evidence That PharmaJet’s Precision Delivery Devices Improve Nucleic Acid Vaccine Performance

Retrieved on: 
목요일, 2월 23, 2023
Biotechnology, Pharmaceutical, Health, Medical Devices, Stratis, Tissue, Safety, HIV, Orthohantavirus, University of Cape Town, Vaccine (journal), DNA, University, Antigen, Bureau of Oceans and International Environmental and Scientific Affairs, Molecular medicine, Injection, Infection, Cell, Use, MDPI, Trial of the century, Subcutaneous tissue, TROPI, Therapy, Probability, Human, Drugs Controller General of India, Multimedia, Messenger, Vaccine, COVID-19, RNA

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    The COVID-19 pandemic increased visibility of nucleic acid vaccines, such as messenger RNA (mRNA), that provide scalability and can be quickly adapted as new variants appear.
  • Historical limitations can be addressed with new administration technologies such as modern needle-free precision delivery systems.
  • “We currently have eighty-three studies ongoing with novel pharmaceuticals focusing on nucleic acid technology in addition to other new vaccine technology platforms.
  • We believe that our precision delivery devices have the potential to increase the performance and therefore probability of regulatory success of many of these candidate vaccines.”
    Refer to Instructions for Use to ensure safe injections and to review risks.

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

Retrieved on: 
월요일, 2월 20, 2023
Society, Dana–Farber Cancer Institute, Circulatory system, Perk, Tokyo Stock Exchange, Temozolomide, Mothers (Tokyo Stock Exchange), Tissue, Brain mapping, Integrin alpha M, HIV disease progression rates, Immunohistochemistry, Harvard Medical School, Glioblastoma, Society for Brain Mapping and Therapeutics, Professor, Therapy, Biopsy, Cleveland Clinic, CD74, Congress, Molecular medicine, TMZ, Part, CD3, Neoplasm, Code, Principal, Doctor of Philosophy, Medicine, Medical imaging, Neurology

MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.

Key Points: 
  • MN-166-GBM-1201; NCT03782415) at the 20th Annual World Congress of SBMT (Society for Brain Mapping and Therapeutics) held on February 16 - 19, 2023, in Los Angeles, CA.
  • This tumor analysis study was a collaborative effort between MediciNova, Dr. Patrick Wen (Dana- Farber Cancer Institute), and Dr. Lathia (Cleveland Clinic Foundation).
  • Immunohistochemistry was performed on resected tumor tissue to evaluate MIF (macrophage migration inhibitory factor), pERK, Ki67, CD3, CD11b, and CD74.
  • Recently, we have completed study enrollment with MN-166-GBM-1201 study and look forward to the upcoming data analysis with more tissue samples.”

Feinstein Institutes researcher discovers potential therapeutic target for lethal sepsis

Retrieved on: 
금요일, 2월 3, 2023
Managed Care, Research, General Health, Pharmaceutical, Infectious Diseases, Hospitals, University, Education, Publishing, Clinical Trials, Science, Communications, Health, Weatherall Institute of Molecular Medicine, Mouse, Infection, Science Advances, Patient, Septic, Credit, Shock, Inflammation, Feinstein Institutes for Medical Research, Medical research, Death, Molecular medicine, Disease, Bacteria, Multimedia, Drug discovery, COVID-19, Medicine, Immunosuppression, Doctor of Philosophy, MD, Pharmaceutical industry, Vaccine, Sepsis

Scientists from the Feinstein Institutes for Medical Research recently published in Science Advances the discovery of a novel protein that could be a potential therapeutic target for lethal sepsis.

Key Points: 
  • Scientists from the Feinstein Institutes for Medical Research recently published in Science Advances the discovery of a novel protein that could be a potential therapeutic target for lethal sepsis.
  • (Credit: Feinstein Institutes)
    Affecting nearly 50 million people worldwide, sepsis occurs when the body’s immune system triggers excessive inflammation in an attempt to help fight against infections.
  • The new study, led by Feinstein Institutes’ Haichao Wang, PhD, focuses on finding protein mediators that may contribute to uncontrolled immune responses to lethal infections.
  • Last year, Dr. Wang earned the Shock Society’s 2021 Scientific Achievements Award for his years of commitment and contribution to sepsis research.

RION Announces the Advisory Appointments of John Ballantyne, Ph.D., to Chair of the Rion Scientific Advisory Board and Andrew D. Badley, M.D., to Chair of the Rion Medical Advisory Board

Retrieved on: 
수요일, 1월 25, 2023
Biotechnology, Cosmetics, Retail, Health, Manufacturing, Pharmaceutical, Research, Other Retail, General Health, Fitness & Nutrition, Science, Other Manufacturing, Clinical Trials, Medical Supplies, North Dakota State University, Vaccine, Collection, Physician, GMP, Government, Mayo Clinic, SARS-CoV-2, Central Institute of Technology, Kokrajhar, Danaher, Therapy, Dalhousie University, Central Institute for Experimental Animals, Autumn, Development, Retirement, The Co Founder, Rion, University, Division, Cardiology, CSO, Entrepreneurship, Infection, United States Air Force Scientific Advisory Board, HIV, DRS, Exosome, Immune system, Wound healing, Molecular medicine, Ballantyne, COVID-19, Badley, Medical device, Pharmacy

RION, a clinical-stage regenerative medicine company with breakthrough platform technology leveraging platelet-derived exosomes, announces the appointment of Dr. Ballantyne as Chair of the company’s Scientific Advisory Board and Dr. Andrew D. Badley as Chair of the Rion Medical Advisory Board.

Key Points: 
  • RION, a clinical-stage regenerative medicine company with breakthrough platform technology leveraging platelet-derived exosomes, announces the appointment of Dr. Ballantyne as Chair of the company’s Scientific Advisory Board and Dr. Andrew D. Badley as Chair of the Rion Medical Advisory Board.
  • “We are honored to have Dr. Ballantyne and Dr. Badley as a part of the Rion team,” said Dr. Atta Behfar, Rion CEO and Co-Founder.
  • Dr. Ballantyne holds undergraduate degrees in Pharmacy from the Central Institute of Technology and the University of Otago in New Zealand.
  • “Dr.

Atomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable Diseases

Retrieved on: 
수요일, 1월 25, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Cloud, AIX, GitHub, University of California, Berkeley, Biology, General partnership, RNA, University, Playground Global, Nat, Molecular medicine, UC, University of California, San Diego, Antheia, Machine learning, Drug discovery, UCSD, Phosphorus, Vaccine, AI

“To create effective and safer small molecules against undruggable diseases, there is a significant need to develop tools that can accurately predict 3D RNA structures,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.

Key Points: 
  • “To create effective and safer small molecules against undruggable diseases, there is a significant need to develop tools that can accurately predict 3D RNA structures,” said Raphael Townshend, Ph.D., Founder and CEO of Atomic AI.
  • “Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology.
  • Beyond RNA-targeted molecules, the integrated platform will also enable the design of RNA-based medicines and RNA tools.
  • “Atomic has created a sophisticated and integrated AI engine that will transform the discovery and development of RNA-targeted medicines.”

Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy

Retrieved on: 
화요일, 1월 31, 2023
Survival, Heart, Myocardial injury after non-cardiac surgery, OTCQB, Liver, Ageing, Brain, Molecular medicine, Gene expression, Animal, Biochemistry, George Washington University School of Medicine & Health Sciences, Lung, Kidney, Thymosin, Regeneration, George Washington University School of Engineering and Applied Science, Research, Pharmaceutical industry

Using the heart as a model experimental system, a research team from Hungary and the United States summarized and expanded upon their previous results regarding Thymosin beta 4 (Tβ4) to support their anti-aging hypothesis.

Key Points: 
  • Using the heart as a model experimental system, a research team from Hungary and the United States summarized and expanded upon their previous results regarding Thymosin beta 4 (Tβ4) to support their anti-aging hypothesis.
  • Their research proved that Tβ4 is expressed in the developing heart and promotes cardiac cell migration and survival.
  • Finally, the researchers discovered Tβ4 is capable of epicardial progenitor activation, and revealed the effect is independent of hypoxic injury.
  • The publication is entitled, Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies; Int Immunopharmacol.

Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research

Retrieved on: 
목요일, 1월 26, 2023
PDUFA, Miller, Tauopathy, University, ALS, Ionis Pharmaceuticals, Neurology, Lewy body dementias, Hope, Pharmacokinetics, Nusinersen, Breakthrough Prize, Huntington's disease, Rain, IONS, Palsy, DRS, Breakthrough Prize in Life Sciences, Washington University School of Medicine, Prescription Drug User Fee Act, Alzheimer's disease, Molecular medicine, Hereditary Disease Foundation, Brain, Oligonucleotide, Patient, University of California, Research, BPS Barbara Wilson Lifetime Achievement Award, Neurodegenerative disease, Pharmaceutical industry, Ionis, Science

CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research.

Key Points: 
  • CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Chief Scientific Officer C. Frank Bennett, Ph.D., has been named a co-recipient of the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research.
  • The prizes will be presented during the Eurotau 2023 conference on April 27, 2023, in Lille, France.
  • Bennett, Cleveland and Miller are being recognized for their work advancing antisense technology for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease and tauopathies.
  • A founding member of Ionis, Dr. Bennett is responsible for continuing to advance Ionis' technology and expand its discovery platform.

Rainwater Charitable Foundation Announces Fourth-Annual Rainwater Prize Winners for Brain Research

Retrieved on: 
목요일, 1월 26, 2023
Miller, Conference, Presidential Early Career Award for Scientists and Engineers, Research group, Neurology, Washington University School of Medicine, FDA, Huntington's disease, Brain, Molecular medicine, Disease, Engineering, Innovation, DSM-IV codes, Tauopathy, DZNE, Biophysics, ASO, Nervous system, DRS, SMA, Biology, Neurodegenerative disease, Progressive supranuclear palsy, Neuron, Messenger, DNA, University of California, San Diego, UCSD, Alzheimer's disease, Washington University in St. Louis, Drug discovery, Cell, Tau, Parkinson's disease, University, ALS, German Center for Neurodegenerative Diseases, Distinguishing, Nusinersen, Rain, SOD1, Wegmann, Pharmaceutical industry, Research, Ionis

FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist. This year's Outstanding Innovation Prize will be awarded to a team: Dr. C. Frank Bennett, Ionis; Dr. Don W. Cleveland, University of California San Diego (UCSD); and Dr. Timothy M. Miller, Washington University. Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist. The prizes will be presented during the Eurotau 2023 Conference on April 27, 2023 in Lille, France.

Key Points: 
  • FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist.
  • Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist.
  • Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research will be shared by:
    Collaborators Drs.
  • "I could not be more excited about this year's winners of the Rainwater Prize," said Todd Rainwater, Trustee of the Rainwater Charitable Foundation.

Rainwater Charitable Foundation Announces Fourth-Annual Rainwater Prize Winners for Brain Research

Retrieved on: 
목요일, 1월 26, 2023
Miller, Conference, Presidential Early Career Award for Scientists and Engineers, Research group, Neurology, Washington University School of Medicine, FDA, Huntington's disease, Brain, Molecular medicine, Disease, Engineering, Innovation, DSM-IV codes, Tauopathy, DZNE, Biophysics, ASO, Nervous system, DRS, SMA, Biology, Neurodegenerative disease, Progressive supranuclear palsy, Neuron, Messenger, DNA, University of California, San Diego, UCSD, Alzheimer's disease, Washington University in St. Louis, Drug discovery, Cell, Tau, Parkinson's disease, University, ALS, German Center for Neurodegenerative Diseases, Distinguishing, Nusinersen, Rain, SOD1, Wegmann, Pharmaceutical industry, Research, Ionis

FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist. This year's Outstanding Innovation Prize will be awarded to a team: Dr. C. Frank Bennett, Ionis; Dr. Don W. Cleveland, University of California San Diego (UCSD); and Dr. Timothy M. Miller, Washington University. Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist. The prizes will be presented during the Eurotau 2023 Conference on April 27, 2023 in Lille, France.

Key Points: 
  • FORT WORTH, Texas, Jan. 26, 2023 /PRNewswire/ -- The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative disease research, today announced this year's recipients of the Rainwater Annual Prize for Outstanding Innovation in Neurodegenerative Disease Research and for Innovative Early Career Scientist.
  • Dr. Susanne Wegmann, German Center for Neurodegenerative Diseases (DZNE) will be awarded the Rainwater Prize for Innovative Early-Career Scientist.
  • Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research will be shared by:
    Collaborators Drs.
  • "I could not be more excited about this year's winners of the Rainwater Prize," said Todd Rainwater, Trustee of the Rainwater Charitable Foundation.